| Prev Close | 572.40 |
| Day Low/High | 566.04 / 577.05 |
| 52 Wk Low/High | 299.22 / 664.64 |
Regeneron Pharmaceuticals, Inc. (REGN)
576.90
4.50
0.79
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 106.39B |
| Market Cap | 60.90B |
| P/E Ratio | 22.19 |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: Here's How We're Going to Beat Covid-19
Let's talk about what's happening right now to get this thing under control and what it will look like not that long from now.
Jim Cramer: Here's Why the President Is Gambling With Stimulus
The market is reflecting a triumph of big business over small business, and here's what that means for individual stocks.
Jim Cramer: The President's Behavior Towards Covid-19
I know that Trump's going to blunt our community mask initiative because who needs masks if it isn't a big deal if you are sick?
Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
Real Money Post Industrial Average Outperforms Major Indexes in September
The RMPIA rose 13.8% during the quarter, leaving it up just shy of 29% on a year-to-date basis, thanks to performance by CRM, AAPL , NKE and TMO.
Jim Cramer: Does Everyone Out There Perceive That Everything Is a Win?
It's remarkable to see such excitement based on totally contradictory theories and themes.
Strength in Regeneron Stock May Not Last Long
The charts of REGN could use more than media coverage.
Jim Cramer: What Investors Should Watch and Expect This Week
This is what's known as a positioning week, and starting Monday you're going to hear a ton of things.
Jim Cramer: You Heard the Ugly of the Debate. Here's the Good.
Neither candidate seems to be the enemy of the market -- at least not yet.
Kass: Does a Possible Biden Bump in Equities Lie Ahead?
I would not view what appears to be an increasingly likely Democratic victory as a reason to sell stocks.
Will We See a 'Biden Bump' Which May Levitate Stocks Throughout the Balance of the Year?
* The 2016 Presidential election provided the contrary - a Trump win and an advancing stock market * The 2020 Presidential election may provide another contrary - a Biden win and an advancing market * President Trump's path to victory is narrowing *...
Debate Spin, Slowing Recovery, Stimulus Hope, Notes on Regeneron, Disney, Tesla
Markets now look to Treasury Secretary Mnuchin and Speaker Pelosi to do something.
Regeneron Cocktail News Good for Happy Hour
"Just one more thing." -- Lt. Columbo The positive Regeneron antibody cocktail news underscores something that I planned to discuss in my opener tomorrow (Is This The Biden Bump?) Specifically, the market has already completed a consolidation phase ...
Sanofi Could Trade Sideways for the Weeks Ahead
I would consider SNY a hold at this point in time.
Weakening Dollar, Fiscal Relief Gridlock, Walmart+, Trading Albemarle
Also, interpreting Tuesday's market, Covid-19 vaccine update, and manufacturing growth.
Here's How I'm Trading XBiotech
Do these shares get back to the 2020 highs that were reached back in January?
Riding the Rails: I Like the Technical Set-Up at Union Pacific
Should the economy see some organic growth, this stock can run as high as $220.
The Rally Broadens, Dow Theory, Virus Cocktail, 4 Questions: Market Recon
Markets may believe that we are closer to the effective use of vaccines and therapeutics than we know in this battle against Covid-19.
Jim Cramer: No Shinola! Sellers Are Wrong on These 3 Stocks
Wendy's, Regeneron and Teladoc -- why would you unload them now?
Jim Cramer: Betting Against Science Is a Mug's Game
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.
Regeneron Stock Is Not Cheap - But It Could Be Undervalued
Ask yourself: Would you pay a higher multiple for the company that puts together a successful cocktail for Covid-19?
Parabolic AMD, Agreeing to Agree, Disney's GAAP Earnings Gap: Market Recon
It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.
Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Charting the Stocks of 3 Covid Treatment Companies
Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.
Jim Cramer: Here's My Sore Thumb Index
This is how you can tell which camp is winning and which is losing in this time of Covid-contradiction.
Real Money Post Industrial Average Outperforms, Despite Outbreak
The RMPIA rebounded more than 22% in the June quarter to finish up 7.8% at the 2020 half mark.
Novavax and Its $1.6 Billion Award Just Got My Attention
The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.
